NCT02424799View on ClinicalTrials.gov

Study to Investigate Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of GSK2646264

PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

November 17, 2014

Primary Completion Date

November 10, 2017

Study Completion Date

November 10, 2017

Conditions
Urticaria
Interventions
DRUG

GSK2646264 0.5% topical cream

GSK2646264 0.5% topical cream is supplied as white-to-off-white aqueous cream stored in amber glass jars

DRUG

GSK2646264 1% topical cream

GSK2646264 1% topical cream is supplied as white-to-off-white aqueous cream stored in amber glass jars

DRUG

Placebo

Placebo topical cream is supplied as white-to-off-white aqueous cream stored in amber glass jars

Trial Locations (6)

10117

GSK Investigational Site, Berlin

14050

GSK Investigational Site, Berlin

NR4 7UY

GSK Investigational Site, Norwich

NR4 7U

GSK Investigational Site, Norwich

SE1 9RT

GSK Investigational Site, London

SE1 9R

GSK Investigational Site, London

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT02424799 - Study to Investigate Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of GSK2646264 | Biotech Hunter | Biotech Hunter